Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Menopausal Estrogen Therapy Benefits and Risks Vary by Age, WHI Analysis Suggests
(Posted: 05/20/2011) - Long-term follow-up data from the Women’s Health Initiative (WHI) provide important new information about the potential risks and benefits of hormone therapy to treat symptoms or conditions related to menopause, including its effect on breast cancer risk, according to results published April 5, 2011, in the Journal of the American Medical Association.
- Adding Radiation to Chemotherapy May Improve Outcomes in Early-Stage Hodgkin Lymphoma
(Posted: 05/12/2011) - Adding radiation therapy to chemotherapy may improve outcomes in patients with early-stage Hodgkin lymphoma, according to a paper published in the Cochrane Database of Systematic Reviews in February 2011, but the long-term effects of this regimen are not known.
- Trastuzumab after Chemotherapy Is Effective in HER2-Positive Breast Cancer
(Posted: 05/06/2011) - Treatment with trastuzumab for 1 year following standard chemotherapy improved disease-free survival in women with HER2-positive early breast cancer, according to 4-year follow-up results of the Herceptin Adjuvant (HERA) trial reported February 25, 2011, in Lancet Oncology.
- Sentinel Lymph Node Occult Metastases Have Minimal Survival Effect in Node-Negative Breast Cancer Patients
(Posted: 04/26/2011) - Detailed examination of sentinel lymph node tissue from breast cancer patients revealed previously unidentified metastases in about 16% of the samples, but the difference in 5-year survival between patients with and without these metastases was very small and likely not clinically meaningful. The results were published in the February 3, 2011 New England Journal of Medicine.
- Denosumab Reduces Risk of Bone Side Effects in Advanced Prostate Cancer
(Posted: 04/13/2011) - The biological agent denosumab (Xgeva) is more effective than zoledronic acid at decreasing the risk of bone fractures and other skeletal-related events (SRE) in men with castration-resistant metastatic prostate cancer, according to results from a randomized clinical trial reported online February 25, 2011, in The Lancet.